Share
The COVID-19 pandemic has further emphasized the need for specialty nurses who understand how to care for patients with chronic diseases. The demand for these caregivers is only going to intensify in coming years as healthcare delivery evolves and becomes even more complex. It has now been a century since the discovery of insulin, a...
Share
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to AZP-3601, Amolyt Pharma’s clinical candidate for the treatment of hypoparathyroidism. “We believe the FDA’s granting of Orphan Drug Designation to AZP-3601 reflects the agency’s recognition that new and more effective treatment options are needed for this serious endocrine disorder,” says Endocrine...
Share
As 2020 winds down, Endocrine News is taking a quick jaunt down memory lane to focus on the many accomplishments the Endocrine Society had over the course of the last 12 months. Despite various obstacles and upended plans, 2020 turned out to be a remarkable year for progress and successful new endeavors. We were somewhere...
Share
[Editor’s note: This post has been updated to clarify that the meta-analysis published in Diabetologia and the Phase IIb trial were separate studies.] Earlier this fall, Phase IIb topline results of the DIAGNODE-2 trial demonstrated a potential type 1 diabetes vaccine GAD-alum — an immunomodulating antigen-specific therapy – had a highly significant and clinically relevant...
Share
Two pharmaceutical companies will collaborate to optimize and evaluate growth hormone receptor antagonists to select a candidate for clinical development as a potential treatment for acromegaly Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, and PeptiDream Inc., a public Kanagawa-based biopharmaceutical company, today announced a research collaboration...
Share
A treatment for obesity and osteoporosis could be on the horizon as Mount Sinai researchers have developed a first-in-class humanized antibody to the follicle-stimulating hormone (FSH) that will reduce body fat, increase bone mass, enhance metabolism, and lower cholesterol. The antibody has the potential to prevent and treat obesity, osteoporosis, and hypercholesterolemia — diseases that...
Share
According to a new guideline from the European Society of Endocrinology, patients with obesity should be routinely tested for thyroid function. However, testing for other endocrine-related conditions should be guided by the presence of symptoms. The endocrine system and obesity can have a push-pull relationship. Some endocrine disorders — such as hypothyroidism and Cushing’s syndrome...
Share
A drug combo of dapagliflozin and exenatide continues to stay effective at controlling the progression of type 2 diabetes, without loss of effect, after two years of continual use, according to a study recently published in Diabetes Care. In a multi-center double-blind, phase 3, randomized controlled trial, a total of 695 adults whose type 2...
